Defence Therapeutics to Attend Bio International Convention in Boston, June 2025
Defence Therapeutics (OTCQB: DTCFF) has announced its participation in the BIO International Convention in Boston from June 16-19, 2025. The company's CEO and COO will attend this prestigious event, which attracts over 20,000 industry leaders worldwide. At the convention, Defence will showcase its Accum® technology, designed to enhance antibody-drug conjugates (ADCs) efficacy and improve tumor-killing capabilities.
The BIO International Convention serves as a vital platform for networking, fostering collaborations, and exploring investment opportunities in the biotechnology sector. Defence aims to leverage this event to advance discussions with potential partners and investors, supporting its mission to develop next-generation cancer therapies.
Defence Therapeutics (OTCQB: DTCFF) ha annunciato la sua partecipazione al BIO International Convention che si terrà a Boston dal 16 al 19 giugno 2025. Il CEO e il COO dell'azienda saranno presenti a questo evento prestigioso, che attira oltre 20.000 leader del settore a livello mondiale. Durante la convention, Defence presenterà la sua tecnologia Accum®, progettata per potenziare l'efficacia dei coniugati anticorpo-farmaco (ADC) e migliorare la capacità di eliminazione dei tumori.
Il BIO International Convention rappresenta una piattaforma fondamentale per il networking, la promozione di collaborazioni e l'esplorazione di opportunità di investimento nel settore biotecnologico. Defence intende sfruttare questa occasione per approfondire le trattative con potenziali partner e investitori, sostenendo la sua missione di sviluppare terapie oncologiche di nuova generazione.
Defence Therapeutics (OTCQB: DTCFF) ha anunciado su participación en la Convención Internacional BIO en Boston del 16 al 19 de junio de 2025. El CEO y el COO de la empresa asistirán a este prestigioso evento, que reúne a más de 20,000 líderes de la industria a nivel mundial. En la convención, Defence presentará su tecnología Accum®, diseñada para mejorar la eficacia de los conjugados anticuerpo-fármaco (ADC) y potenciar la capacidad de destrucción tumoral.
La Convención Internacional BIO es una plataforma clave para establecer contactos, fomentar colaboraciones y explorar oportunidades de inversión en el sector biotecnológico. Defence busca aprovechar este evento para avanzar en las conversaciones con posibles socios e inversores, apoyando su misión de desarrollar terapias contra el cáncer de nueva generación.
Defence Therapeutics (OTCQB: DTCFF)는 2025년 6월 16일부터 19일까지 보스턴에서 열리는 BIO 국제 컨벤션에 참가한다고 발표했습니다. 회사의 CEO와 COO가 참석하는 이 권위 있는 행사에는 전 세계 20,000명 이상의 업계 리더들이 모입니다. 컨벤션에서 Defence는 항체-약물 결합체(ADC)의 효능을 향상시키고 종양 제거 능력을 강화하기 위해 설계된 Accum® 기술을 선보일 예정입니다.
BIO 국제 컨벤션은 네트워킹, 협력 촉진, 바이오테크 투자 기회 탐색을 위한 중요한 플랫폼입니다. Defence는 이 행사를 활용해 잠재 파트너 및 투자자와의 논의를 진전시키고 차세대 암 치료제 개발이라는 사명을 지원할 계획입니다.
Defence Therapeutics (OTCQB : DTCFF) a annoncé sa participation à la Convention Internationale BIO à Boston du 16 au 19 juin 2025. Le PDG et le COO de l'entreprise assisteront à cet événement prestigieux, qui réunit plus de 20 000 leaders du secteur à travers le monde. Lors de la convention, Defence présentera sa technologie Accum®, conçue pour améliorer l'efficacité des conjugués anticorps-médicament (ADC) et renforcer les capacités de destruction tumorale.
La Convention Internationale BIO constitue une plateforme essentielle pour le réseautage, la promotion de collaborations et l'exploration d'opportunités d'investissement dans le secteur biotechnologique. Defence souhaite tirer parti de cet événement pour avancer dans ses discussions avec des partenaires et investisseurs potentiels, soutenant ainsi sa mission de développer des thérapies anticancéreuses de nouvelle génération.
Defence Therapeutics (OTCQB: DTCFF) hat seine Teilnahme an der BIO International Convention in Boston vom 16. bis 19. Juni 2025 angekündigt. Der CEO und COO des Unternehmens werden an dieser renommierten Veranstaltung teilnehmen, die über 20.000 Branchenführer aus aller Welt anzieht. Auf der Konferenz wird Defence seine Accum®-Technologie präsentieren, die darauf ausgelegt ist, die Wirksamkeit von Antikörper-Wirkstoff-Konjugaten (ADCs) zu verbessern und die Tumorbekämpfung zu optimieren.
Die BIO International Convention dient als wichtige Plattform zum Networking, zur Förderung von Kooperationen und zur Erkundung von Investitionsmöglichkeiten im Biotechnologiesektor. Defence plant, diese Veranstaltung zu nutzen, um Gespräche mit potenziellen Partnern und Investoren voranzutreiben und seine Mission zur Entwicklung neuartiger Krebstherapien zu unterstützen.
- None.
- None.
Montreal, Quebec--(Newsfile Corp. - May 28, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing advanced cancer therapeutics and drug delivery technologies, is pleased to announce that its Chief Executive Officer and Chief Operating Officer will be attending the prestigious BIO International Convention, taking place in Boston from June 16-19, 2025. This event brings together global leaders in biotechnology and pharmaceuticals, providing a unique opportunity for Defence to engage with key stakeholders and showcase its innovative technologies.
The BIO International Convention is recognized as the largest and most comprehensive event in the biotechnology sector, attracting over 20,000 industry leaders from around the world. The conference serves as a vital platform for networking, fostering collaborations, and exploring investment opportunities. The event offers invaluable opportunities for both chance encounters and pre-scheduled meetings with investors, partners, and collaborators, making it an essential event for companies seeking to expand their reach and impact within the biotech and pharma industries.
At this year's convention, Defence will highlight the significant potential of its Accum® technology, designed to enhance the efficacy of antibody-drug conjugates ("ADCs") and improve tumor-killing capabilities—even with ADCs previously considered to have limited therapeutic potential. By participating in BIO 2025, Defence seeks to advance discussions with prospective partners and investors, furthering its mission to deliver next-generation cancer therapies.
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253579
FAQ
When and where is Defence Therapeutics (DTCFF) attending the BIO International Convention?
What technology will Defence Therapeutics showcase at BIO 2025?
How many industry leaders attend the BIO International Convention?
What is the purpose of Defence Therapeutics' participation in BIO 2025?
